Novartis crashes after drug trial backfires

BlickIndependentCenter4 hr. ago

The article reports on significant stock price declines for Novartis, noting a two-day drop with losses exceeding 10% and marking the largest loss since 2020. The decline follows disappointing clinical trial results for a new muscle disease treatment, adding to previous setbacks with heart medication trials. Despite recent gains after positive data on multiple sclerosis treatments, the current losses have erased much of the year’s gains. The Swiss market index SMI also fell due to Novartis' performance.

Bias read (Center): The article presents factual financial developments related to Novartis and the Swiss stock market without overt ideological framing. It focuses on corporate performance and market reactions rather than political advocacy or partisan commentary. While pharmaceutical companies and regulatory issues (

watsonIndependentCenter5 hr. ago

Novartis shares fell sharply after a failed clinical trial for a drug candidate targeting muscle disease. The stock dropped over 10% in early trading following disappointing results from the Harbor study testing Del-desiran for myotonic dystrophy type 1. Analysts expressed concern about investor confidence, particularly regarding drugs acquired through the purchase of Avidity Biosciences, despite other promising candidates from that acquisition. While the primary goal of improving hand movement speed was not met, Novartis noted some indications of efficacy in secondary measures. This marks the second setback for Novartis in days, following earlier disappointing results for another drug, Pelacarsen.

Bias read (Center): The article reports on financial market reactions to pharmaceutical research outcomes without taking a stance on political issues. It focuses on economic impacts and corporate performance rather than political decisions, policies, or figures.